Day: March 25, 2025

Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosisLong-term disability and safety data from ALITHIOS open-label extension study on continuous treatment with Kesimpta vs. later switch from teriflunomide in relapsing multiple sclerosis (RMS) patients to be presentedAdditional presentations highlight the Novartis neuroscience pipeline, including remibrutinib for RMS and iptacopan for generalized myasthenia gravisBasel, March 25, 2025 – Novartis will present data from studies across its neuroscience portfolio, including seven-year disability outcomes and safety data from the ALITHIOS open-label extension trial of Kesimpta® (ofatumumab) in people with relapsing multiple sclerosis (RMS), at the American Academy of Neurology (AAN) 2025...

Ladies and Gentlemen Please find enclosed the invitation to the Ascom Annual General Meeting 2025. This will take place on Wednesday, April 16, 2025, at 2 p.m.The venue is the Theater Casino Zug, Artherstrasse 2-4, 6300 Zug. Further details on the meeting and the agenda can be found in the official invitation enclosed. Yours sincerelyAscom Holding AGAttachmentAscom_Invitation_AGM_2025

HIGHLIGHTS:Montage to obtain up to 19.9% ownership stake in African Gold (ASX:A1G), through the issuance of up to 2.19 million common shares for deemed aggregate consideration of up to circa C$6.3 million African Gold to appoint Silvia Bottero, EVP Exploration of Montage, as Non-Executive Director and Martino De Ciccio, CEO of Montage, as Strategic Advisor to the Board of Directors African Gold owns several exploration properties in Côte d’Ivoire, including its flagship Didievi project which hosts an Inferred Resource of 4.93Mt at 2.9 g/t Au containing 452,000oz of gold, as published by African Gold Montage appointed operator of the Didievi project to take advantage of its presence and expertise in Côte d’Ivoire African Gold is currently undertaking a 10,000-meter drill programme at its Didievi project which continues to return high-grade...

HOUSTON, March 24, 2025 (GLOBE NEWSWIRE) — Prairie Operating Co. (“Prairie,” the “Company,” “we,” or “our”) (Nasdaq: PROP) announced today the pricing of an underwritten public offering of $38.5 million (the “Common Stock Offering”) of shares of its common stock, par value $0.01 (“Common Stock”) at a price to the public of $4.50 per share. The underwriters have a 30-day option to purchase up to an aggregate value of $5.8 million of additional shares of Common Stock. Net proceeds to Prairie from the sale of the $38.5 million of shares of its common stock, after the underwriting discount and commissions and estimated offering expenses, will be approximately $35.4 million (or $40.8 million, if the underwriters exercise their option in full). The Company intends to use the net proceeds from the Common Stock Offering, together with...

Tokyo, Japan and Cambridge, UK, 25 March 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner Tempero Bio, Inc. has initiated a Phase 2 trial of TMP-301, a potent, selective and orally available mGluR5 negative allosteric modulator (NAM), for the treatment of alcohol use disorder (Clinical Trial ID: NCT06648655). The full announcement from Tempero Bio can be found by clicking here, in which Tempero Bio also announces the close of a $70 million financing, the proceeds of which will be used to advance TMP-301 through the Phase 2 trial for alcohol use disorder and a second Phase 2 trial in cocaine use disorder planned to start over the next year. The funds will also be used by Tempero Bio to conduct Phase 3-enabling activities for TMP-301 and preclinical studies for additional indications and formulations. The...